Serotonin syndrome following methylene blue administration during cardiothoracic surgery

Journal of Pharmacy Practice

Volumn 28, Issue 2, 2015, Pages 207-211

  Smith, Christina J ^a   Wang, Dorothy ^a   Sgambelluri, Anna ^a   Kramer, Robert S ^a   Gagnon, David J ^a  

^a MAINE MEDICAL CENTER   (United States)

Author keywords

cardiology; cardiothoracic surgery; encephalopathy; methylene blue; serotonin syndrome

Indexed keywords

METHYLENE BLUE; POLITEF; TRAZODONE; VENLAFAXINE;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; BRAIN TOXICITY; CASE REPORT; CLONUS; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY BYPASS GRAFT; DRUG DOSE REDUCTION; DRUG SAFETY; ELECTROENCEPHALOGRAM; ELECTROENCEPHALOGRAPHY; FEMALE; HUMAN; INTRAAORTIC BALLOON PUMP; MIDDLE AGED; MITRAL VALVE REPAIR; NEW YORK HEART ASSOCIATION CLASS; SEROTONIN METABOLISM; SEROTONIN SYNDROME; SINGLE DRUG DOSE; TIC; CHEMICALLY INDUCED; MITRAL VALVE; SURGERY;

CORONARY ARTERY BYPASS; FEMALE; HUMANS; METHYLENE BLUE; MIDDLE AGED; MITRAL VALVE; SEROTONIN SYNDROME;

EID: 84927628091     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190014568389     Document Type: Article

References (25)

1. Fischer GW, Levin MA. Vasoplegia during cardiac surgery: current concepts and management. Semin Thorac Cardiovasc Surg. 2010 ; 22 (2). 140-144
2. Argenziano M, Choudhri AF, Oz MC, et al. A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation. 1997 ; 96: 286S - 90S
3. Levin MA, Lin HM, Castillo JG, et al. Early on-cardiopulmonary bypass hypotension and other factors associated with vasoplegic syndrome. Circulation. 2009 ; 120 (17). 1664-1671
4. Mekontso-Dessap A, Houel R, Soustelle C, et al. Risk factors for post-cardiopulmonary bypass vasoplegia in patients with preserved left ventricular function. Ann Thorac Surg. 2001 ; 71 (5). 1428-1432
5. Lenglet S, Mach F, Monecucco F. Methylene blue: potential use of an antique molecule in vasoplegic syndrome during cardiac surgery. Expert Rev Cardiovasc Ther. 2011 ; 9 (12). 1519-1525
6. Argenziano M, Chen JM, Choudhri AF, et al. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. J Thorac Cardiovasc Surg. 1998 ; 116 (6). 973-980
7. Shanmugam G. Vasoplegic syndrome-the role of methylene blue. Eur J Cardiothorac Surg. 2005 ; 28 (5). 705-710
8. Ozal E, Kuralay E, Yildirim, et al. Preoperative methylene blue administration in patients at high risk for vasoplegic syndrome during cardiac surgery. Ann Thorac Surg. 2005 ; 79 (5). 1615-1619
9. Levin RL, Degrange MA, Bruno GF, et al. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg. 2004 ; 77 (2). 496-499
10. Maslow AD, Sterans G, Butala P, et al. The hemodynamic effects of methylene blue when administered at the onset of cardiopulmonary bypass. Anesth Analg. 2006 ; 103 (1). 2-8
11. Leyh RG, Kofidis T, Struber, et al. Methylene blue: the drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass?. J Thorac Cardiovasc Surg. 2003 ; 125 (6). 1426-1431
12. Ng BK, Cameron AJ. The role of methylene blue in serotonin syndrome: a systematic review. Psychosomatics. 2010 ; 51 (3). 194-200
13. Sweet G, Standiford SB. Methylene-blue-associated encephalopathy. J Am Coll Surg. 2007 ; 204 (3). 454-458
14. Shopes E, Gerard W, Baughman J. Methylene blue encephalopathy: a case report and review of published cases. AANA J. 2013 ; 81 (3). 215-221
15. Grubb KJ, Kennedy JL, Bergin JD, et al. The role of methylene blue in serotonin syndrome following cardiac transplantation: a case report and review of the literature. J Thorac Cardiovasc Surg. 2012 ; 144 (5). e113 - e116
16. Shanmugam G, Kent B, Alsaiwadi T, et al. Serotonin syndrome following cardiac surgery. Interact Cardiovasc Thorac Surg. 2008 ; 7 (4). 656-657
17. Wainwright M, Amaral L. The phenothiazinium chromophore and the evolution of antimalarial drugs. Trop Med Int Health. 2005 ; 10 (6). 501-511
18. Wright RO, Lewander WJ, Woolf AD. Methemoglobinemia: etiology, pharmacology, and clinical management. Ann Emerg Med. 1999 ; 34 (5). 646-656
19. Kirov MY, Evgenov OV, Evgenov NV, et al. Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study. Crit Care Med. 2001 ; 29 (10). 1860-1867
20. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005 ; 352 (11). 1112-1120
21. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981 ; 30 (2). 239-245
22. Ramsay RR, Dunford C, Gillman PK. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Br J Pharmacol. 2007 ; 152 (6). 946-951
23. Petzer A, Harvey BH, Wegener G, et al. Azure B, a metabolite of methylene blue, is a high-potency, reversible inhibitor of monoamine oxidase. Toxicol Appl Pharmacol. 2012 ; 258 (3). 403-409
24. Kirschner R, Donovan JW. Serotonin syndrome precipitated by fentanyl during procedural sedation. J Emerg Med. 2010 ; 38 (4). 477-480
25. McDonagh DL, Berger M, Mathew JP, et al. Neurological complications of cardiac surgery. Lancet Neurol. 2014 ; 13 (5). 490-502